![Franck Grimaud](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Franck Grimaud
Directeur/Membre du Conseil chez IOMAI CORPORATION
Fortune : 2 M $ au 30/09/2024
Profil
Franck Charles Marie Grimaud founded Vivalis SA in 1999, where he worked as President, CEO & Head-Investor Relations from 2010 to 2013.
Mr. Grimaud also currently works at Intercell USA, Inc., as Director & Deputy Chief Executive Officer from 2015, Atlantic Biotherapies, as Chief Executive Officer & Director, Valneva USA, Inc., as Director & Deputy Chief Executive Officer from 2015, Pays de la Loire Participations, as Chairman-Governing Board from 2016, Atlanpole Biotherapies, as Chairman from 2018, Fonds Pays De La Loire Participations, as Chairman-Governing Board from 2016, Valneva Scotland Ltd., as Director from 2017, VALNEVA Austria GmbH, as Co-Managing Director from 2013, Vaccines Holdings Sweden AB, as Director & Managing Director from 2014, BliNK Biomedical SAS, as Director, Valneva Sweden AB, as Director from 2015, Valneva UK Ltd., as Director from 2015, Valneva Canada, Inc., as Director & President from 2015, Valneva SE, as Chief Business Officer, and Intercell Austria AG, as Chief Business Officer from 2013.
Mr. Grimaud also formerly worked at Vivalis Toyama Japan KK, as Chairman from 2013 to 2018, France Biotech Association, as Director, Smol Therapeutics SAS, as President & Managing Director, Grimaud Deyang Animal Co. Ltd., as Director from 2000 to 2019, and Chengdu Grimaud Breeding Co. Ltd., as Director from 2000 to 2018.
Mr. Grimaud received his Masters Business Admin degree from the University of Ottawa.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VALNEVA SE
0,39% | 31/12/2023 | 635 218 ( 0,39% ) | 2 M $ | 30/09/2024 |
Dernières actualités sur Franck Grimaud
Postes actifs de Franck Grimaud
| Sociétés | Poste | Début |
|---|---|---|
| VALNEVA | Corporate Officer/Principal | - |
| IOMAI CORPORATION | Directeur/Membre du Conseil | 01/12/2015 |
Valneva Scotland Ltd.
 Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Directeur/Membre du Conseil | 01/06/2017 |
Atlanpole Biotherapies
 Atlanpole Biotherapies Miscellaneous Commercial ServicesCommercial Services Atlanpole Biotherapies provides immunotherapy, regenerative medicine, and radio pharmacy bio cluster services. The company is based in Nantes, France. | Président | 01/02/2018 |
BliNK Biomedical SAS
 BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Directeur/Membre du Conseil | - |
Pays de la Loire Participations
 Pays de la Loire Participations Investment ManagersFinance Investissement pour le Développement des Entreprises l'Emploi is designed to invest in small and mid cap companies based in the Pays de la Loire region of France. The fund will invest mainly in innovative companies with a profitable track record and help them in their growth by taking minority participation. | Directeur/Membre du Conseil | 01/09/2016 |
| Valneva USA, Inc. | Directeur Général | 01/12/2015 |
| Intercell Austria AG | Corporate Officer/Principal | 01/01/2013 |
Valneva Canada, Inc.
 Valneva Canada, Inc. Medical DistributorsDistribution Services Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The company is based in Kirkland, Canada. | President | 01/01/2015 |
| ░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Franck Grimaud
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░ ░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░ ░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Franck Grimaud
| University of Ottawa | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VALNEVA | Health Technology |
| Entreprise privées | 19 |
|---|---|
Vivalis SA
 Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | Health Technology |
Vaccines Holdings Sweden AB
 Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Health Technology |
| Smol Therapeutics SAS | |
| Vivalis Toyama Japan KK | |
| Grimaud Deyang Animal Co. Ltd. | |
| Chengdu Grimaud Breeding Co. Ltd. | |
| Atlantic Biotherapies | |
Valneva Austria GmbH
 Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Commercial Services |
France Biotech Association
 France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Commercial Services |
Intercell USA, Inc.
 Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Valneva Scotland Ltd.
Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Health Technology |
Valneva UK Ltd.
 Valneva UK Ltd. Medical/Nursing ServicesHealth Services Part of Valneva SE, Valneva UK Ltd. provides health care services. The company is based in London, UK and was founded in 2015. | Health Services |
Valneva Sweden AB
 Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Health Technology |
Valneva Canada, Inc.
Valneva Canada, Inc. Medical DistributorsDistribution Services Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The company is based in Kirkland, Canada. | Distribution Services |
| Intercell Austria AG | |
| Valneva USA, Inc. | |
Pays de la Loire Participations
Pays de la Loire Participations Investment ManagersFinance Investissement pour le Développement des Entreprises l'Emploi is designed to invest in small and mid cap companies based in the Pays de la Loire region of France. The fund will invest mainly in innovative companies with a profitable track record and help them in their growth by taking minority participation. | Finance |
BliNK Biomedical SAS
BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Health Technology |
Atlanpole Biotherapies
Atlanpole Biotherapies Miscellaneous Commercial ServicesCommercial Services Atlanpole Biotherapies provides immunotherapy, regenerative medicine, and radio pharmacy bio cluster services. The company is based in Nantes, France. | Commercial Services |
